Search results
Apr 25, 2024 · We are at the forefront of developing a new class of therapeutics that may address the root cause of many diseases of aging. By selectively eliminating or modulating senescent cells, we may restore aging or damaged tissues to a more functionally healthy state. Learn More.
Unity Biotechnology is a publicly traded American biotechnology company that develops drugs that target senescent cells.
WE ASPIRE TO DEVELOP TRANSFORMATIVE MEDICINES TO SLOW, HALT, OR REVERSE DISEASES OF AGING. Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease.
UNITY’s most advanced drug candidate, UBX1325, is currently being evaluated for the treatment of age-related diseases of the eye – including diabetic macular edema. The small molecule targets Bcl-xL, a protein that senescent cells rely on for survival.
Mar 15, 2022 · UNITY Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating medicines that target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases, while leveraging partnerships in growth areas with high unmet need.
Find the latest Unity Biotechnology, Inc. (UBX) stock quote, history, news and other vital information to help you with your stock trading and investing.
ASPIRE is a multi-center, randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept in previously treated patients with active diabetic macular edema (DME) who are not achieving optimal benefit from standard of care.
